Global Antifungal Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Antifungal Drugs Market is presumed to reach the market size of nearly USD 31.85 Billion by 2032 from USD 21.52 Billion in 2023 with a CAGR of 4.45% under the study period 2024-2032.

Antifungal drugs refer to a pharmaceutical fungicide primarily used to treat many infections like candidiasis, ringworms, athletes' feet, and others. These drugs can easily be purchased through a doctor's prescription, whereas some are available over the counter. Fungal infections arise due to organism feed by breaking down the living tissues, also known as dermatophytes. They can utilize keratin protein and cause infection over hair, skin, and nails. The only purpose of these drugs is to inhibit the fungal cell from growing by making the cell's content break out. An unhygienic environment may drive to a severe condition in causing an infection on the skin.

MARKET DYNAMICS

The growth of this market can be attributed to rising awareness about the products' availability through online advertisement along with a wide range of products. In addition to this, increasing occurrences of immunological diseases and changing environmental conditions, and the rise in the spread of many infectious diseases from individual to individual are also boosting the demand. A rising number of fungal infections like aspergillosis and candidiasis are also upsurging the demand during the forecast period. However, the availability of substitute is hindering the market growth. At the same time, the adoption of advanced technologies in manufacturing many drugs and providing effective treatment procedures for diverse infectious diseases globally is ready to create a new avenue for market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Antifungal Drugs. The growth and trends of Antifungal Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Antifungal Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Azoles
Echinocandins
Polyenes
Allylamines
Others

By Indication

Dermatophytosis
Aspergillosis
Candidiasis
Others

By Dosage Form

Oral Drugs
Ointments
Powders
Others

By Distribution Channel

Hospital Pharmacies
Retails Pharmacies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antifungal Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antifungal Drugs market include Novartis AG, Pfizer Inc., Bayer AG, Sanofi, Merck & Co. Inc., GlaxoSmithKline Plc, Abbott, Glenmark, Enzon Pharmaceuticals Inc., Astellas Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11214197

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ANTIFUNGAL DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Dosage Form
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTIFUNGAL DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data
5.3. Analysis By Drug Class
5.4. Azoles Historic and Forecast Sales By Regions
5.5. Echinocandins Historic and Forecast Sales By Regions
5.6. Polyenes Historic and Forecast Sales By Regions
5.7. Allylamines Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL ANTIFUNGAL DRUGS MARKET ANALYSIS BY INDICATION

6.1. Overview By Indication
6.2. Historical and Forecast Data
6.3. Analysis By Indication
6.4. Dermatophytosis Historic and Forecast Sales By Regions
6.5. Aspergillosis Historic and Forecast Sales By Regions
6.6. Candidiasis Historic and Forecast Sales By Regions
6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL ANTIFUNGAL DRUGS MARKET ANALYSIS BY DOSAGE FORM

7.1. Overview By Dosage Form
7.2. Historical and Forecast Data
7.3. Analysis By Dosage Form
7.4. Oral Drugs Historic and Forecast Sales By Regions
7.5. Ointments Historic and Forecast Sales By Regions
7.6. Powders Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ANTIFUNGAL DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data
8.3. Analysis By Distribution Channel
8.4. Hospital Pharmacies Historic and Forecast Sales By Regions
8.5. Retails Pharmacies Historic and Forecast Sales By Regions
8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL ANTIFUNGAL DRUGS MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ANTIFUNGAL DRUGS COMPANIES

10.1. Antifungal Drugs Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF ANTIFUNGAL DRUGS INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Novartis AG
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Pfizer Inc.
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Bayer AG
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Sanofi
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Merck & Co. Inc.
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. GlaxoSmithKline Plc
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Abbott
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Glenmark
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Enzon Pharmaceuticals Inc.
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Astellas Pharma Inc
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies